DRW Securities’s Oric Pharmaceuticals ORIC Stock Holding History

DRW Securities’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,194	Closed	-$157K	–	1612
2025 Q4	$157K	Buy	+19,194	New	+$221K	﹤0.01%	1014

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

DRW Securities's ORIC Position: Q1 2026 in Review

DRW Securities sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 19,194 shares — an estimated $157K sold.

DRW Securities first reported a position in ORIC in Q4 2025 and held it in 1 quarter. The position peaked at $157K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

DRW Securities reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 19,194 Oric Pharmaceuticals shares in Q1 2026, an estimated $157K.
DRW Securities first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 1 quarter.
DRW Securities's Oric Pharmaceuticals position peaked at $157K in Q4 2025.
182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.